Table 3.
In vitro antibacterial activity (MIC) of trichogin GA IV and its analogs against antibiotic-resistant clinical isolates of S.aureus, A. baumannii, and P. aeruginosa.
| No. | MIC/MBC (μg/mL) a | |||||||
|---|---|---|---|---|---|---|---|---|
|
S. aureus ATCC 43300 (MRSA) |
A. baumannii SI-12 (OXA-23) |
A. baumannii SI-648 (OXA-23, OXA-51-like) |
A. baumannii SI-310 (OXA-24) |
P. aeruginosa VR-143/97 (VIM-1) |
P. aeruginosa VA-182/00 (VIM-2) |
P. aeruginosa 506/99 (VIM-2) |
P. aeruginosa 101/1477 (IMP-1) |
|
| 1 | 2/2 | 4/8 | 8/16 | 4/4 | 32/32 | 16/16 | 16/32 | 8/16 |
| 2 | 2/4 | 32/32 | 16/32 | 32/32 | >128 | >128 | >128 | >128 |
| 4 | 4/8 | 2/4 | 4/4 | 4/8 | 16/32 | 16/32 | 16/16 | 8/16 |
| 4b | 8/8 | 4/4 | 4/4 | 4/8 | 32/64 | 32/64 | 32/32 | 32/64 |
| 5 | 2/2 | 4/4 | 4/4 | 2/4 | 8/8 | 8/8 | 8/8 | 8/8 |
| 5b | 2/2 | 4/8 | 4/4 | 2/4 | 16/32 | 8/32 | 8/32 | 8/8 |
| 6 | 4/8 | - | - | - | - | - | - | - |
| 7 | 4/8 | 2/4 | 2/4 | 4/4 | 8/8 | 8/8 | 8/8 | 8/8 |
| 9 | 4/8 | 32/32 | 32/32 | 32/32 | >128 | >128 | >128 | >128 |
| 10 | 4/8 | 32/32 | 16/16 | 16/16 | >128 | >128 | >128 | >128 |
| 11 | 2/2 | 32/32 | 2/4 | 2/4 | 8/8 | 8/32 | 8/16 | 8/8 |
a Minimum Inhibitory Concentrations and Minimum Bactericidal Concentrations are reported for each compound, unless no significant direct antibacterial activity could be detected (MIC, >128 µg/mL); MIC between 2 and 8 µg/mL are highlighted in bold, with a green background. -, not determined. The resistance determinants or phenotypes (see Table 4 for details) are indicated between parentheses for each isolate (MRSA, methicillin resistant S. aureus; OXA-23, OXA-24, and OXA-51-like are class D carbapenem-hydrolyzing β-lactamases; IMP-1, VIM-1, and VIM-2 are metallo-β-lactamases).